Therapy Directory

Docetaxel clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Docetaxel as a study intervention. Browse Docetaxel recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 12:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1320

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Head and Neck Cancer
Interventions: Nivolumab, Cisplatin, Docetaxel, Intensity-modulated radiotherapy; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Atlanta, Georgia • Boston, Massachusetts • St Louis, Missouri + 1 more

Conditions: Carcinoma, Non-small Cell Lung Cancer
Interventions: nivolumab, ipilimumab, cabozantinib, docetaxel, ramucirumab, lucitanib; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Breast Cancer
Interventions: Nivolumab 360mg, Paclitaxel 80mg/m^2, Doxorubicin 60mg/m^2, Cyclophosphamide 600mg/m^2, Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2, Trastuzumab 8mg/kg and 6 mg/kg, Pertuzumab 840mg and 420mg; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Bloomington, Indiana • New York, New York

Conditions: Prostate Cancer
Interventions: DKN-01, Docetaxel; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 1 more

Conditions: Metastatic Triple Negative Breast Cancer
Interventions: L-NMMA, Docetaxel, Amlodipine, Pegfilgrastim, Enteric-coated aspirin; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: bicalutamide, docetaxel, goserelin, intensity-modulated radiation therapy; Drug · Radiation
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Advanced Gastric Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
Interventions: ibrutinib, everolimus, paclitaxel, docetaxel, cetuximab, pembrolizumab; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 44
States / cities: Huntsville, Alabama • Gilbert, Arizona • Tucson, Arizona + 39 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Olaparib, Placebo, Abiraterone, Prednisone or prednisolone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Male only
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 2
States / cities: San Diego, California • Lake Success, New York

Conditions: NSCLC Stage IV, NSCLC Stage IIIB
Interventions: Ipatasertib; Drug
Lead sponsor: Jun Zhang, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: Fairway, Kansas • Kansas City, Kansas • Overland Park, Kansas + 2 more

Conditions: Prostate Cancer
Interventions: GnRh (Leuprolide), Testosterone Gel, Docetaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Aging
Interventions: Not listed
Lead sponsor: Sapere Bio; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Birmingham, Alabama • Chapel Hill, North Carolina

Conditions: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
Interventions: OR2805, Cemiplimab, Docetaxel; Drug
Lead sponsor: OncoResponse, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Scottsdale, Arizona • Austin, Texas • San Antonio, Texas

About this Docetaxel clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Docetaxel as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Docetaxel.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Docetaxel clinical trials

Filter and sort this therapy

Live official records

Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy

Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer

Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

About this Docetaxel clinical trials directory page